Downloads: 14
Case Studies | Medicine | Volume 12 Issue 6, June 2023 | Pages: 99 - 103 | India
Case Report: Dasatinib Induced Pulmonary Hypertension in a Case of CML
Abstract: Dasatinib was identified to be associated with pulmonary arterial hypertension. There is still very little data on clinical characteristics of this severe complication. When a 51 - year - old male presented with worsening dyspnea was diagnosed with pulmonary arterial hypertensionin a background of CML and managed with standard comprehensive care, including replacement of other tyrosine kinase inhibitor, administration of pulmonary vasodilators. Our case suggests that dasatinib - induced pulmonary arterial hypertension may be partially reversible when diagnosed early, managed with target therapy of pulmonary arterial hypertension, providing new insight into the rare complication.
Keywords: CML - Chronic myelogenous leukemia, TKIs - tyrosine kinase inhibitors, DASA - Dasatinib, PAH - Pulmonary artery hypertension
How to Cite?: Dr. Abhishek Padhiar, Dr. Ankit Agarwal, "Case Report: Dasatinib Induced Pulmonary Hypertension in a Case of CML", Volume 12 Issue 6, June 2023, International Journal of Science and Research (IJSR), Pages: 99-103, https://www.ijsr.net/getabstract.php?paperid=SR23529100847, DOI: https://dx.doi.org/10.21275/SR23529100847